Merck + Co., Inc.

Merck Sharp + Dohme Corp.

Merck Frosst Canada, Inc.

Lin Chu

Mark T Goulet

Matthew J Wyvratt

Feroze Ujjainwalla

Thomas F Walsh

Michael H Fisher

Bing Li

Anthony K Ogawa

Wallace T Ashton

Hyun O Ok

Peter Lin

Jonathan R Young

Jinyou Xu

Debra L Ondeyka

Narindar N Girotra

Ihor E Kopka

Rosemary Sisco

Minal J Patel

Stephanie L Witkin

Helmut H Mrozik

Mitree M Ponpipom

James Francis Dropinski

Lan Wei

Guizhen Dong

Vincent Colandrea

Alexander J Kim

John Howard Hutchinson

Tesfaye Biftu

Yves Girard

Dong Xiao

Jinlong Jiang

Michel Therien

Robert R Wilkening

Zhicai Wu

Danqing D Feng

Iyassu Sebhat

Richard Frenette

William R Schoen

XiaoXia Qian

Linda L Chang

Ping Chen

Rajan Anand

Robert L Bugianesi

Petr Vachal

John J Acton, Iii

Jacqueline D Hicks

James M Apgar

Kenneth J Leavitt

Deyou Sha

Fengqi Zhang

Roy G Smith

Feng Ye

Todd K Jones

Yi Zang

Dwight Macdonald

Ellen K Vande Bunte

Daniel Warner

Yi Tien Yang

Bonnie Louridas

Aaron Lackner

Xiaoxia Qian

Ramesh S Kashi

Annette Bak

John J Iii Acton

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. 

Cyclic amine substituted heterocyclic CETP inhibitors

Cyclohexyl sulfonamide compounds which are platelet-activating factor (PAF) receptor antagonists. Said compounds may be useful, for example, for the treatment of atherosclerosis or other PAF-mediated disorders, including inflammatory, cardiovascular, and immune disorders.

Platelet-activating factor receptor antagonists

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension. 

Cyclic azabenzimidazole derivatives useful as anti-diabetic agents

The instant invention provides compounds of formula I which are 5-lipoxygenase activating protein inhibitors.  Compounds of formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Diphenyl substituted alkanes as flap inhibitors

This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions. 

Benzimidazole and aza-benzimidazole carboxamides

The instant invention provides compounds of Formula I which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents. 

Diphenyl substituted alkanes

The instant invention provides compounds of Formula II which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula II are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.

Diaryl substituted alkanes

The instant invention provides compounds of formula: (I) which are 5-lipoxygenase activating protein inhibitors: formula (I). Compounds of formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cyto-protective agents. 

Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use

Certain novel 4-substituted N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

Acylated piperidine derivatives as melanocortin-4 receptor agonists

There are disclosed compounds of formula (I)

Antagonists of gonadotropin releasing hormone

There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.

There are disclosed compounds of formula (I) ##STR1## and pharmaceutically acceptable salts thereof which are useful as antagonists of GnRH and as such may be useful for the treatment of a variety of sex-hormone related and other conditions in both men and women.

Growing community of inventors

Scotch Plains, NJ, United States of America

Lin Chu